vVARDIS is a Swiss healthcare company pioneering a new category of dental care: non-invasive treatment of early-stage tooth decay. Our flagship Curodont® products are the first clinically validated treatment for early-stage cavities that helps preserve the natural tooth structure and enables the restoration of enamel crystal density throughout the lesion, in a similar way to how nature built the tooth, without drilling, needles or anesthesia.

Tooth decay is the #1 disease in the world affecting approximately 2.5 billion people globally, according to the World Health Organization. For decades, the options for early-stage cavities have been "watch-and-wait" or "drill-and-fill." Since our U.S. launch in January 2024, Curodont® has been sold into more than 20,000 dental practices and applied to over 3.5 million teeth in the U.S. alone. 

Our Class A ordinary shares are listed on the New York Stock Exchange (NYSE) under the symbol "VVVV".